AER Cases Could Be Prosecuted Under Kickback Statute – U.S. Atty. Sheehan
This article was originally published in The Tan Sheet
Executive Summary
The federal anti-kickback statute is broad enough to allow prosecution of pharmaceutical manufacturers for inadequate reporting of adverse events, Philadelphia Assistant U.S. Attorney James Sheehan maintained during a recent Food & Drug Law Institute meeting in Washington, D.C
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning